Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Invigor Medical vs AquaVita NextGen

Two GLP-1 desks, one scoreboard. We put Invigor Medical and AquaVita NextGen head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 9 · Grade B+

Invigor Medical

Visit Invigor Medical Full brief →
vs
No. 176 · Grade C

AquaVita NextGen

Visit AquaVita NextGen Full brief →

The verdict

Invigor Medical takes this head-to-head.

Invigor Medical scores 88 to 67 on our six-factor Brief Score — An established telehealth pharmacy with a broad metabolic and hormone catalog and a steady price line.

That doesn't make AquaVita NextGen a bad call — it's best for patients in az/ca/fl/tx/nv seeking medspa-backed glp-1 with a named medical director. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
87
36
Supply Reliability
88
71
Transparency
84
88
Access Breadth
82
62
Clinical Oversight
88
82
Track Record
90
73
Invigor MedicalBrief Score 88 · 67AquaVita NextGen

Price, coverage & the tracker

Invigor MedicalAquaVita NextGen
Brief Score88/100 (B+)67/100 (C)
Semaglutide$199/moFrom $375/mo (compounded)
Tirzepatide$339/moFrom $320/mo (starting dose, compounded)
CoverageNot disclosed5 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

Invigor Medical: Long-running operator; mid-market pricing unchanged this cycle.

AquaVita NextGen: New to the tracker on 1 August 2026. The published line reads From $320/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.